TY  - JOUR
AU  - Cottu, Paul
AU  - Ring, Alistair
AU  - Abdel-Razeq, Hikmat
AU  - Marchetti, Paolo
AU  - Cardoso, Fatima
AU  - Salvador Bofill, Javier
AU  - Martín, Miguel
AU  - Menon-Singh, Lakshmi
AU  - Wu, Jiwen
AU  - De Laurentiis, Michelino
PY  - 2022
DO  - 10.1016/j.breast.2022.01.016
UR  - http://hdl.handle.net/10668/22064
T2  - Breast (Edinburgh, Scotland)
AB  - The phase IIIb CompLEEment-1 study evaluated ribociclib plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). Outcomes were investigated in the...
LA  - en
KW  - Advanced breast cancer
KW  - CDK4/6 inhibitor
KW  - Endocrine therapy
KW  - Ribociclib
KW  - Aminopyridines
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - Female
KW  - Hormones
KW  - Humans
KW  - Letrozole
KW  - Purines
KW  - Receptor, ErbB-2
KW  - Receptors, Estrogen
KW  - Receptors, Progesterone
TI  - Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial.
TY  - research article
VL  - 62
ER  -